Document Detail

Chymopapain chemonucleolysis in lumbar disk disease.
MedLine Citation:
PMID:  123015     Owner:  NLM     Status:  MEDLINE    
Experience with chymopapain chemonucleolysis in 1,200 cases of lumbar disk disease indicates that it is an effective method of relieving pain resulting from an abnormal intervertebral disk. Complications were few; anaphylaxis occurring immediately after injection was by far the most serious. With the use of a corticosteroid and an antihistamine in preoperative preparation, the incidence of anaphylaxis had dropped, although it still occurs. On long-term follow-up, chemonucleolysis appears to be as good as laminectomy in properly selected cases.
L L Wiltse; E R Widell; H A Yuan
Related Documents :
15077935 - Guidelines for case reports of adverse events related to acupuncture.
24960135 - Dural prostate metastasis resembling a chronic subdural haematoma.
11030485 - Possible induction of mania and hypomania by olanzapine or risperidone: a critical revi...
23589105 - Ultrathin nanostructures: smaller size with new phenomena.
21435415 - Caffeine and cardiac arrhythmias: a review of the evidence.
14652485 - Visualization of spinal injection procedures using gadolinium contrast.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  JAMA     Volume:  231     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  1975 Feb 
Date Detail:
Created Date:  1975-05-13     Completed Date:  1975-05-13     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  474-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anaphylaxis / chemically induced
Back Pain / drug therapy
Drug Evaluation
Drug Evaluation, Preclinical
Follow-Up Studies
Injections, Spinal
Intervertebral Disc / drug effects*,  radiography
Intervertebral Disc Displacement / drug therapy*,  radiography
Peptide Hydrolases / administration & dosage,  adverse effects,  therapeutic use*
Sciatica / drug therapy
Time Factors
Reg. No./Substance:
EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of Dictyocaulus viviparus infection in Rocky Mountain elk in Teton County, Wyoming.
Next Document:  Blood flow velocity in the carotid artery as a measure of myocardial contractility.